Information about Atomoxetine
Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily for therapy of attention deficit hyperactivity disorder.
Liver safety of Atomoxetine
Atomoxetine has been linked to a low rate of serum aminotransferase elevations and to rare cases of acute, clinically apparent liver injury.
Mechanism of action of Atomoxetine
Atomoxetine (a" toe mox' e teen) is a selective norepinephrine reuptake inhibitor that blocks the presynaptic norepinephrine transporter leading to an increase in levels of this potent neurotransmitter, predominantly in the central nervous system. Therapy with atomoxetine has been shown to lead to improvements in levels of psychological functioning and performance in children and adults with suspected attention deficit hyperactivity disorder.
FDA approval information for Atomoxetine
Atomoxetine was approved for use in adults, adolescents and children above the age of 6 years with attention deficit hyperactivity disorder in the United States in 2002. Atomoxetine is available in capsules of 10, 18, 25, 40, 60, 80 and 100 mg in generic forms and under the brand name Strattera. The recommended initial dosage in adults is 40 mg once daily, with subsequent increases to a maintenance dose which averages 60 to 100 mg daily. The dosage in children is based upon body weight.
Side effects of Atomoxetine
Common side effects include headache, insomnia, irritability, dry mouth, erectile dysfunction, urinary hesitancy, gastrointestinal upset, nausea, constipation and rash. Uncommon but potentiall severe adverse events include suicidal ideation and behavior, cardiovascular symptoms and events, manic or aggressive behavior and hypersensitivity reactions.
The following are CNS stimulants
- Amphetamines (including ecstasy or methylenedioxymetamphetamine)